Drug Investigation

, Volume 5, Issue 5, pp 281–284 | Cite as

Disposition and Clinical Effects of Moclobemide and Three of its Metabolites following Overdose

  • L. Peter Hackett
  • David A. Joyce
  • Rodger W. Hall
  • Leon J. Dusci
  • Kenneth F. Ilett
Case Report

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. DaPrada M, Kettler R, Keller HH, Haefely WE. Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. Modem Problems of Pharmacopsychiatry 19: 231–245, 1983Google Scholar
  2. Fitton A, Faulds D, Goa KL. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561–596, 1992PubMedCrossRefGoogle Scholar
  3. Geschke R, Komer J, Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. Journal of Chromatography 420: 111–120, 1987PubMedCrossRefGoogle Scholar
  4. Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfmger P, et al. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatrica Scandinavica 82 (Suppl. 360): 91–93, 1990CrossRefGoogle Scholar
  5. Maguire K, Pereira A, Tiller J. Moclobemide pharmacokinetics in depressed patients: lack of an age effect. Human Psychopharmacology 6: 249–252, 1991CrossRefGoogle Scholar
  6. Moll E, Hetzel W. Moclobemide (RO 11-1163) safety in depressed patients. Acta Psychiatrica Scandinavica 360 (Suppl.): 69–70, 1990PubMedCrossRefGoogle Scholar
  7. Myrenfors PG, Eriksson T, Sandstedt GS, Sjoberg G. Moclobemide overdose. Journal of Internal Medicine 233: 113–115, 1993PubMedCrossRefGoogle Scholar
  8. Pons G, Schoerlin MP, Tam YK, Moran C, Pfefen JP, et al. Moclobemide excretion in breast milk. British Journal of Clinical Pharmacology 29: 27–31, 1990PubMedCrossRefGoogle Scholar
  9. Schoerlin MP, Guentert TW. Pharmakokinetik und Metabolismus reversibler MAO-A Hemmer beim Menschen. Psychiatriche Praxis 16: 11–17, 1989Google Scholar
  10. Schoerlin MP, Horber FF, Frey F, Mayersohn M. Disposition kinetics of moclobemide, a new MAO-A inhibitor in subjects with impaired renal function. Journal of Clinical Pharmacology 30: 272–284, 1990PubMedGoogle Scholar
  11. Stabl M, Biziere K, Schmid-Burgk W, Amrein R. Review of comparative clinical trials: moclobemide vs tricyclic antidepressants and vs placebo in depressive states. Journal of Neural Transmission 28 (Suppl.): 77–89, 1989PubMedGoogle Scholar
  12. Stoeckel K, Pfefen JP, Mayersohn M, Schoerlin MP, Andressen C, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatrica Scandinavica 360 (Suppl.): 94–97, 1990PubMedCrossRefGoogle Scholar
  13. Tiller JWG, Maguire KP, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. International Journal of Geriatric Psychiatry 5: 199–204, 1990CrossRefGoogle Scholar
  14. Vine R, Norman TR, Burrows GD. A case of moclobemide overdose. International Clinical Psychopharmacology 3: 325–326, 1988PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • L. Peter Hackett
    • 1
  • David A. Joyce
    • 1
  • Rodger W. Hall
    • 2
  • Leon J. Dusci
    • 1
  • Kenneth F. Ilett
    • 1
  1. 1.Combined Unit in Clinical Pharmacology and ToxicologyState Health Laboratory Services/University of Western AustraliaNedlandsAustralia
  2. 2.Pharmacy DepartmentSir Charles Gairdner HospitalNedlandsAustralia

Personalised recommendations